TScan Therapeutics CFO Brian Silver resigns; CEO MacBeath appointed interim CFO, Dworak as Principal Accounting Officer

TScan Therapeutics, Inc.

Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.
Leiden Dworak appointed Principal Accounting Officer, effective July 21, 2023; previously VP, Finance since April 2022.
Dworak's base salary increased to $340,000; target bonus raised to 35% from 30%; granted 25,000 stock options at $2.23.
Stock options vest over four years (25% one-year cliff, then monthly). No family relationships or related party transactions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Silver

Chief Financial Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-07-21
Successor: Gavin MacBeath
Filed: July 25, 2023, 7:59 PM ET

replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.

Appointed

Leiden Dworak

Principal Accounting Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-07-21
Filed: July 25, 2023, 7:59 PM ET

appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023

Appointed (interim)

Gavin MacBeath

interim Principal Financial Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-07-21
Filed: July 25, 2023, 7:59 PM ET

appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Silver resigned as Chief Financial Officer at TScan Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Leiden Dworak was appointed as Principal Accounting Officer at TScan Therapeutics, Inc..

Action: appointed
Role: Principal Accounting Officer

Exact text from the filing

appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath was appointed as interim Principal Financial Officer at TScan Therapeutics, Inc..

Action: appointed
Role: interim Principal Financial Officer

Exact text from the filing

appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-192484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.